Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ASH 2011—Hodgkin’s disease and the high grade lymphomas

ASH 2011—Hodgkin’s disease and the high grade lymphomas In advanced Hodgkin’s disease, a new standard of therapy was defined by the results of the HD15 trial where 6 cycles of therapy according to the BEACOPPescalated regime translated into an impressive superior longterm survival compared to more intensive alternative approaches due to reduced toxicity and less secondary malignancies. Furthermore, PET guided allocation of consolidating radiotherapy to residual masses avoided unnecessary radiation in two-thirds of patients in the HD15 trial. Excessive radiotherapy was also proofed to be detrimental in early stage disease in the framework of the NCIC CTG/ECOG HD.6 trial. Rituximab was shown to be an effective, although not curative treatment in the early “Nodular lymphocyte predominant Hodgkin’s Lymphoma” (NLPHL) subtype in several series. The remaining challenge in Hodgkin’s disease is the optimisation of therapy in elderly patients, the only patient subgroup still underperforming. In aggressive lymphomas, no definite changes of therapeutic standards could be deduced from this year’s ASH meeting while multiple new therapeutics are still in phase I and II studies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

ASH 2011—Hodgkin’s disease and the high grade lymphomas

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/ash-2011-hodgkin-s-disease-and-the-high-grade-lymphomas-fpiM7oDFUQ

References (11)

Publisher
Springer Journals
Copyright
Copyright © 2012 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-012-0028-x
Publisher site
See Article on Publisher Site

Abstract

In advanced Hodgkin’s disease, a new standard of therapy was defined by the results of the HD15 trial where 6 cycles of therapy according to the BEACOPPescalated regime translated into an impressive superior longterm survival compared to more intensive alternative approaches due to reduced toxicity and less secondary malignancies. Furthermore, PET guided allocation of consolidating radiotherapy to residual masses avoided unnecessary radiation in two-thirds of patients in the HD15 trial. Excessive radiotherapy was also proofed to be detrimental in early stage disease in the framework of the NCIC CTG/ECOG HD.6 trial. Rituximab was shown to be an effective, although not curative treatment in the early “Nodular lymphocyte predominant Hodgkin’s Lymphoma” (NLPHL) subtype in several series. The remaining challenge in Hodgkin’s disease is the optimisation of therapy in elderly patients, the only patient subgroup still underperforming. In aggressive lymphomas, no definite changes of therapeutic standards could be deduced from this year’s ASH meeting while multiple new therapeutics are still in phase I and II studies.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 21, 2012

There are no references for this article.